Clinical trial · Interventional
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies such as etanercept may interfere with the growth of the cancer cells. Combining chemotherapy with biological therapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects of giving arsenic trioxide together with etanercept and to see how well it works in treating patients with myelodysplastic syndromes.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic/Myeloproliferative Diseases | Myelodysplastic/Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| arsenic trioxide | Drug | Arsenic Trioxide | ALIAS |
| etanercept | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Hematologic response in patients with intermediate-2 or high-risk myelodysplastic syndromes
- measure
- Efficacy of this regimen in patients with intermediate-1 or low-risk MDS that was refractory to anti-thymocyte globulin and etanercept on protocol FHCRC-1872
- measure
- Correlate results of ex vivo and in vitro studies on phenotypic, cytogenetic, and functional disease characteristics with in vivo treatment responses
- measure
- Parameters that are associated with a high probability of response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of myelodysplastic syndromes (MDS) meeting 1 of the following criteria: * Intermediate-2 or high-risk disease * Intermediate-1 or low-risk disease that was refractory to anti-thymocyte globulin and etanercept on protocol FHCRC-1872 * Not eligible for stem cell transplantation for any of the following reasons: * Suitable bone marrow donor is not available * Ineligible for a transplantation protocol * Not willing to undergo transplantation PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count \> 500/mm\^3 Hepatic * Not specified Renal * Not specified Cardiovascular * No evidence of cardiac arrhythmia * No evidence of congestive heart failure * QTc interval ≤ 460 msec Pulmonary * No pneumonia Other * Potassium \> 4.0 mEq/L (supplemental electrolytes allowed) * Magnesium \> 1.8 mg/dL (supplemental electrolytes allowed) * No history of anaphylactic reaction to arsenic trioxide * No active severe infection (e.g., septicemia) within the past 2 weeks * No other severe disease that would preclude study compliance * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics * No prior hematopoietic stem cell transplantation * More than 4 weeks since prior hematopoietic growth factors for MDS * More than 4 weeks since prior immunomodulatory therapy for MDS * No concurrent hematopoietic growth factors for MDS * No other concurrent immunomodulatory therapy for MDS Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * More than 4 weeks since prior cytotoxic therapy for MDS * More than 4 weeks since prior experimental therapy for MDS * No other concurrent cytotoxic therapy for MDS * No other concurrent experimental therapy for MDS
References
Publications (0)
Data not yet available